Clinical Trials Logo

Rosai Dorfman Disease clinical trials

View clinical trials related to Rosai Dorfman Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05915208 Recruiting - Clinical trials for Langerhans Cell Histiocytosis

Histiocytic Disorder Follow-up Study

Start date: September 1, 2022
Phase:
Study type: Observational

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders

NCT ID: NCT04079179 Recruiting - Clinical trials for Neuro-Degenerative Disease

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

NACHO-COBI
Start date: April 19, 2021
Phase: Phase 2
Study type: Interventional

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.